Company: Ulysses Neuroscience Ltd.
Job title: CSO & Head of Ulysses Maynoot
Psychedelics 2.0 – Novel preclinical approaches to investigate mechanisms of action and efficacy of glutamatergic and serotonergic psychedelics 9:15 am
Acute and long-term behavioural and molecular efficacy of ketamine in the rat IFN-alpha model of depression Exploring changes in synaptic markers (BDNF; pre-synaptic SV2A and synaptophysin; post-synaptic PSD-95 and spinophilin) induced by psychedelics Using established and innovative behavioural endpoints to understand psychedelic effects on brain function Preclinical electrophysiology as a translational biomarker of acute and…Read more
day: Day One